<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38369573</PMID><DateCompleted><Year>2024</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial.</ArticleTitle><Pagination><StartPage>811</StartPage><EndPage>821</EndPage><MedlinePgn>811-821</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-024-06092-w</ELocationID><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">Infection with coxsackie B viruses (CVBs) can cause diseases ranging from mild common cold-type symptoms to severe life-threatening conditions. CVB infections are considered to be prime candidates for environmental triggers of type 1 diabetes. This, together with the significant disease burden of acute CVB infections and their association with chronic diseases other than diabetes, has prompted the development of human CVB vaccines. The current study evaluated the safety and immunogenicity of the first human vaccine designed against CVBs associated with type 1 diabetes in a double-blind randomised placebo-controlled Phase I trial.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The main eligibility criteria for participants were good general health, age between 18 and 45 years, provision of written informed consent and willingness to comply with all trial procedures. Treatment allocation (PRV-101 or placebo) was based on a computer-generated randomisation schedule and people assessing the outcomes were masked to group assignment. In total, 32 participants (17 men, 15 women) aged 18-44 years were randomised to receive a low (n=12) or high (n=12) dose of a multivalent, formalin-inactivated vaccine including CVB serotypes 1-5 (PRV-101), or placebo (n=8), given by intramuscular injections at weeks 0, 4 and 8 at a single study site in Finland. The participants were followed for another 24 weeks. Safety and tolerability were the primary endpoints. Anti-CVB IgG and virus-neutralising titres were analysed using an ELISA and neutralising plaque reduction assays, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 32 participants (low dose, n=12; high dose, n=12; placebo, n=8) no serious adverse events or adverse events leading to study treatment discontinuation were observed. Treatment-emergent adverse events considered to be related to the study drug occurred in 37.5% of the participants in the placebo group and 62.5% in the PRV-101 group (injection site pain, headache, injection site discomfort and injection site pruritus being most common). PRV-101 induced dose-dependent neutralising antibody responses against all five CVB serotypes included in the vaccine in both the high- and low-dose groups. Protective titres ≥8 against all five serotypes were seen in &gt;90% of participants over the entire follow-up period.</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">The results indicate that the tested multivalent CVB vaccine is well tolerated and immunogenic, supporting its further clinical development.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT04690426.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">This trial was funded by Provention Bio, a Sanofi company.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hyöty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0370-4145</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. heikki.hyoty@tuni.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland. heikki.hyoty@tuni.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Tampere University Hospital, Tampere, Finland. heikki.hyoty@tuni.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kääriäinen</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Services Turku - CRST Oy, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laiho</LastName><ForeName>Jutta E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0002-5443-4651</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comer</LastName><ForeName>Gail M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Provention Bio, Inc., a Sanofi Company, Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Provention Bio, Inc., a Sanofi Company, Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Härkönen</LastName><ForeName>Taina</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-1068-224X</Identifier><AffiliationInfo><Affiliation>Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehtonen</LastName><ForeName>Jussi P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0009-0007-2168-5765</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikarinen</LastName><ForeName>Sami</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3901-6774</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puustinen</LastName><ForeName>Leena</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-6677-8654</Identifier><AffiliationInfo><Affiliation>Department of Virology, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Provention Bio, Inc., a Sanofi Company, Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>León</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Provention Bio, Inc., a Sanofi Company, Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheinin</LastName><ForeName>Mika</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7579-9126</Identifier><AffiliationInfo><Affiliation>Clinical Research Services Turku - CRST Oy, Turku, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biomedicine, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knip</LastName><ForeName>Mikael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0474-0033</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanjuan</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Provention Bio, Inc., a Sanofi Company, Bridgewater, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04690426</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">Type 1 diabetes</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>21</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>18</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38369573</ArticleId><ArticleId IdType="pmc">PMC10954874</ArticleId><ArticleId IdType="doi">10.1007/s00125-024-06092-w</ArticleId><ArticleId IdType="pii">10.1007/s00125-024-06092-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Khetsuriani N, Lamonte A, Oberste MS, Pallansch M. Neonatal enterovirus infections reported to the national enterovirus surveillance system in the United States, 1983–2003. Pediatr Infect Dis J. 2006;25(10):889–893. doi: 10.1097/01.inf.0000237798.07462.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.inf.0000237798.07462.32</ArticleId><ArticleId IdType="pubmed">17006282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyöty H. Viruses in type 1 diabetes. Pediatr Diabetes. 2016;17(Suppl 22):56–64. doi: 10.1111/pedi.12370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12370</ArticleId><ArticleId IdType="pubmed">27411438</ArticleId></ArticleIdList></Reference><Reference><Citation>Abedi GR (2018) Enterovirus and parechovirus surveillance—United States, 2014–2016. MMWR Morb Mortal Wkly Rep 67(18):515–518. Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6718a2.htm. Accessed 12 Jan 2023 10.15585/mmwr.mm6718a2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5944979</ArticleId><ArticleId IdType="pubmed">29746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention Nonpolio enterovirus and human parechovirus surveillance—United States, 2006–2008. MMWR Morb Mortal Wkly Rep 2010 59(48):1577–1580. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5948a2.htm. Accessed 12 Jan 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">21150865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K, Lynch KF, Wong MC, et al. Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med. 2019;25(12):1865–1872. doi: 10.1038/s41591-019-0667-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0667-0</ArticleId><ArticleId IdType="pmc">PMC6898786</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, Tauriainen S, Oikarinen S, et al. Type 1 diabetes is associated with enterovirus infection in gut mucosa. Diabetes. 2012;61(3):687–691. doi: 10.2337/db11-1157.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-1157</ArticleId><ArticleId IdType="pmc">PMC3282798</ArticleId><ArticleId IdType="pubmed">22315304</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamble DR, Kinsley ML, FitzGerald MG, Bolton R, Taylor KW. Viral antibodies in diabetes mellitus. Br Med J. 1969;3(5671):627–630. doi: 10.1136/bmj.3.5671.627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.3.5671.627</ArticleId><ArticleId IdType="pmc">PMC1984442</ArticleId><ArticleId IdType="pubmed">5811681</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. The prevalence of enteroviral capsid protein vp1 immunostaining in pancreatic islets in human type 1 diabetes. Diabetologia. 2009;52(6):1143–1151. doi: 10.1007/s00125-009-1276-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-009-1276-0</ArticleId><ArticleId IdType="pubmed">19266182</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Edwin B, Buanes T, et al. Detection of a low-grade enteroviral infection in the islets of Langerhans of living patients newly diagnosed with type 1 diabetes. Diabetes. 2015;64(5):1682–1687. doi: 10.2337/db14-1370.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db14-1370</ArticleId><ArticleId IdType="pubmed">25422108</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Edwin B, Buanes T, et al. Pancreatic biopsy by minimal tail resection in live adult patients at the onset of type 1 diabetes: experiences from the DiViD study. Diabetologia. 2014;57(4):841–843. doi: 10.1007/s00125-013-3155-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-013-3155-y</ArticleId><ArticleId IdType="pubmed">24429579</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Krogvold L, Edwin B, et al. Characterisation of enterovirus RNA detected in the pancreas and other specimens of live patients with newly diagnosed type 1 diabetes in the DiViD study. Diabetologia. 2021;64(11):2491–2501. doi: 10.1007/s00125-021-05525-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-021-05525-0</ArticleId><ArticleId IdType="pmc">PMC8494699</ArticleId><ArticleId IdType="pubmed">34390364</ArticleId></ArticleIdList></Reference><Reference><Citation>Geravandi S, Richardson S, Pugliese A, Maedler K. Localization of enteroviral RNA within the pancreas in donors with T1D and T1D-associated autoantibodies. Cell Rep Med. 2021;2(8):100371. doi: 10.1016/j.xcrm.2021.100371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100371</ArticleId><ArticleId IdType="pmc">PMC8385321</ArticleId><ArticleId IdType="pubmed">34467248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarmiento L, Galvan JA, Cabrera-Rode E, et al. Type 1 diabetes associated and tissue transglutaminase autoantibodies in patients without type 1 diabetes and coeliac disease with confirmed viral infections. J Med Virol. 2012;84(7):1049–1053. doi: 10.1002/jmv.23305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23305</ArticleId><ArticleId IdType="pubmed">22585721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ifie E, Russell MA, Dhayal S, et al. Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. Diabetologia. 2018;61(11):2344–2355. doi: 10.1007/s00125-018-4704-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-018-4704-1</ArticleId><ArticleId IdType="pmc">PMC6182664</ArticleId><ArticleId IdType="pubmed">30074059</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufman DL, Erlander MG, Clare-Salzler M, Atkinson MA, Maclaren NK, Tobin AJ. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest. 1992;89(1):283–292. doi: 10.1172/JCI115573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115573</ArticleId><ArticleId IdType="pmc">PMC442846</ArticleId><ArticleId IdType="pubmed">1370298</ArticleId></ArticleIdList></Reference><Reference><Citation>Marttila J, Juhela S, Vaarala O, et al. Responses of coxsackievirus B4-specific T-cell lines to 2C protein-characterization of epitopes with special reference to the GAD65 homology region. Virology. 2001;284(1):131–141. doi: 10.1006/viro.2001.0917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2001.0917</ArticleId><ArticleId IdType="pubmed">11352674</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlton KU. CVB infection and mechanisms of viral cardiomyopathy. Curr Top Microbiol Immunol. 2008;323:315–335. doi: 10.1007/978-3-540-75546-3_15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-75546-3_15</ArticleId><ArticleId IdType="pubmed">18357777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM. Persistent enterovirus infection: little deletions, long infections. Vaccines. 2022;10(5):770. doi: 10.3390/vaccines10050770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050770</ArticleId><ArticleId IdType="pmc">PMC9143164</ArticleId><ArticleId IdType="pubmed">35632526</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogvold L, Genoni A, Puggioni A, et al. Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. Diabetologia. 2022;65(12):2108–2120. doi: 10.1007/s00125-022-05779-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-022-05779-2</ArticleId><ArticleId IdType="pmc">PMC9630231</ArticleId><ArticleId IdType="pubmed">35953727</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindfors K, Lin J, Lee HS, et al. Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study. Gut. 2020;69(8):1416–1422. doi: 10.1136/gutjnl-2019-319809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2019-319809</ArticleId><ArticleId IdType="pmc">PMC7234892</ArticleId><ArticleId IdType="pubmed">31744911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahrs CR, Chuda K, Tapia G, et al. Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort. BMJ. 2019;364:l231. doi: 10.1136/bmj.l231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l231</ArticleId><ArticleId IdType="pmc">PMC6372922</ArticleId><ArticleId IdType="pubmed">30760441</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen M, Puustinen L, Lehtonen J, et al. Enterovirus infections are associated with the development of celiac disease in a birth cohort study. Front Immunol. 2021;11:604529. doi: 10.3389/fimmu.2020.604529.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.604529</ArticleId><ArticleId IdType="pmc">PMC7884453</ArticleId><ArticleId IdType="pubmed">33603739</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacs SR, Roy A, Dance B, et al. Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins. Lancet Diabetes Endocrinol. 2023;11:578–592. doi: 10.1016/S2213-8587(23)00122-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(23)00122-5</ArticleId><ArticleId IdType="pubmed">37390839</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Butrym M, Hankaniemi MM, et al. Coxsackievirus B vaccines prevent infection-accelerated diabetes in NOD mice and have no disease-inducing effect. Diabetes. 2021;70(12):2871–2878. doi: 10.2337/db21-0193.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0193</ArticleId><ArticleId IdType="pmc">PMC8660981</ArticleId><ArticleId IdType="pubmed">34497136</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Hankaniemi MM, Laitinen OH, et al. A hexavalent coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv. 2020;6(19):eaaz2433. doi: 10.1126/sciadv.aaz2433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aaz2433</ArticleId><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson PG, Lakshmikanth T, Laitinen OH, et al. A preclinical study on the efficacy and safety of a new vaccine against coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia. 2015;58(2):346–354. doi: 10.1007/s00125-014-3436-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-014-3436-0</ArticleId><ArticleId IdType="pubmed">25370797</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. doi: 10.1136/bmj.c332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.c332</ArticleId><ArticleId IdType="pmc">PMC2844940</ArticleId><ArticleId IdType="pubmed">20332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermann R, Turpeinen H, Laine AP, et al. DR-DQ-encoded genetic determinants of childhood-onset type 1 diabetes in Finland: an analysis of 622 nuclear families. Tissue Antigens. 2003;62(2):162–169. doi: 10.1034/j.1399-0039.2003.00071.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-0039.2003.00071.x</ArticleId><ArticleId IdType="pubmed">12889996</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilonen J, Kiviniemi M, Lempainen J, et al. Genetic susceptibility to type 1 diabetes in childhood - estimation of HLA class II associated disease risk and class II effect in various phases of islet autoimmunity. Pediatr Diabetes. 2016;17(Suppl 22):8–16. doi: 10.1111/pedi.12327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pedi.12327</ArticleId><ArticleId IdType="pubmed">27411431</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietzak MM, Schofield TC, McGinniss MJ, Nakamura RM. Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles. Clin Gastroenterol Hepatol. 2009;7(9):966–971. doi: 10.1016/j.cgh.2009.05.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2009.05.028</ArticleId><ArticleId IdType="pubmed">19500688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov AP, Dragunsky EM. ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines. Expert Rev Vaccines. 2005;4(2):167–172. doi: 10.1586/14760584.4.2.167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.4.2.167</ArticleId><ArticleId IdType="pubmed">15889990</ArticleId></ArticleIdList></Reference><Reference><Citation>Simhon A, Lifshitz A, Abed Y, Lasch EE, Schoub B, Morag A. How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants. Int J Epidemiol. 1990;19(1):164–168. doi: 10.1093/ije/19.1.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/19.1.164</ArticleId><ArticleId IdType="pubmed">2161806</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N. David Bodian’s contribution to the development of poliovirus vaccine. Am J Epidemiol. 2005;161(3):207–212. doi: 10.1093/aje/kwi033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwi033</ArticleId><ArticleId IdType="pubmed">15671252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Lehtonen JP, Nurminen N, et al. HLA-DQ-conferred risk for type 1 diabetes does not alter neutralizing antibody response to a widely used enterovirus vaccine, the poliovirus vaccine. J Med Virol. 2023;95(4):e28707. doi: 10.1002/jmv.28707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28707</ArticleId><ArticleId IdType="pubmed">36971180</ArticleId></ArticleIdList></Reference><Reference><Citation>Triolo TM, Pyle L, Broncucia H, et al. Association of high-affinity autoantibodies with type 1 diabetes high-risk HLA haplotypes. J Clin Endocrinol Metab. 2022;107(4):e1510–7. doi: 10.1210/clinem/dgab853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgab853</ArticleId><ArticleId IdType="pmc">PMC8947772</ArticleId><ArticleId IdType="pubmed">34850014</ArticleId></ArticleIdList></Reference><Reference><Citation>Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004;53(2):384–392. doi: 10.2337/diabetes.53.2.384.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.2.384</ArticleId><ArticleId IdType="pubmed">14747289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>